anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Non-dissolvable nasal packs (Rapid Rhino and Merocel) are widely used in secondary healthcare centres for the control of epistaxis, with some side effects.
METHODS: A prospective, observational cohort study was conducted of adults who required Rapid Rhino or Merocel packing for acute epistaxis management in a large healthcare centre between March 2020 and 2021. A validated modified version of the 22-item Sino-Nasal Outcome Test was used.
RESULTS: A total of 80 adults requiring non-dissolvable packs were recruited. Seventy per cent of patients had Rapid Rhino packs inserted. Embarrassment was greater in patients who used Rapid Rhino than Merocel. Merocel packs had a significantly higher mean pain score on removal compared to Rapid Rhino. There was no correlation between rebleed rate and type of nasal pack used.
CONCLUSION: Non-dissolvable Rapid Rhino and Merocel nasal packs have similar efficacy in controlling epistaxis. Rapid Rhino packs are more embarrassing for patients in comparison to Merocel packs, but are less painful to remove.
Paternal exposures (and other non-maternal factors) around pregnancy could have important effects on offspring health. One challenge is that data on partners are usually from a subgroup of mothers with data, potentially introducing selection bias, limiting generalisability of findings. We aimed to investigate the potential for selection bias in studies using partner data.We characterise availability of data on father/partner and mother health behaviours (smoking, alcohol, caffeine and physical activity) around pregnancy from three UK cohort studies: the Avon Longitudinal Study of Parents and Children (ALSPAC), Born in Bradford and the Millennium Cohort Study. We assess the extent of sample selection by comparing characteristics of families where fathers/partners do and do not participate. Using the association of parental smoking during pregnancy and child birthweight as an example, we perform simulations to investigate the extent to which missing father/partner data may induce bias in analyses conducted only in families with participating fathers/partners.In all cohorts, father/partner data were less detailed and collected at fewer timepoints than mothers. Partners with a lower socio-economic position were less likely to participate. In simulations based on ALSPAC data, there was little evidence of selection bias in associations of maternal smoking with birthweight, and bias for father/partner smoking was relatively small. Missing partner data can induce selection bias. In our example analyses of the effect of parental smoking on offspring birthweight, the bias had a relatively small impact. In practice, the impact of selection bias will depend on both the analysis model and the selection mechanism.
Sepsis is a life-threatening disease, contributing to significant morbidity and mortality. This study aimed to investigate the association between low muscle mass and the prognosis of patients with biliary sepsis, focusing on outcomes such as length of hospital stay (LOS), intensive care unit (ICU) admission, and in-hospital mortality. This retrospective, single-center, observational study included adult patients with biliary sepsis who visited the emergency department between January 2016 and December 2021. Low muscle mass was assessed using the psoas muscle index (PMI). Using computed tomography imaging, the area of both sides of the psoas muscle at the L3 level was measured, and the PMI, corrected by the patient's height was calculated. The primary outcome was in-hospital mortality, and the secondary outcomes were intensive care unit (ICU) admission, LOS, and 14-day mortality. A total of 745 patients were included in this study. Low muscle mass was defined as a PMI < 421 mm2/m2 for males and < 268 mm2/m2 for females with the lower quartile of PMI according to sex. The cohort was classified into sarcopenic (n = 189) and non-sarcopenic (n = 556) groups. There was a significant association between low muscle mass and in-hospital mortality (odds ratio, 3.81; 95% confidence interval, 1.08-13.47; p < 0.001), while there was no significant association between low muscle mass and ICU admission. In addition, the median LOS in the sarcopenic group (10 [7-14] days) was significantly longer than the median (8 [6-11] days) in the non-sarcopenic group. Low muscle mass was significantly associated with clinical outcomes, particularly in-hospital mortality and LOS, in patients with biliary sepsis.
BACKGROUND: Grade 1/2 PanNETs are mostly managed similarly, typically without any adjunct treatment with the belief that their overall metastasis rate is low. In oncology literature, Ki67-index of 10% is increasingly being used as the cutoff in stratifying patients to different protocols, although there are no systematic pathology-based studies supporting this approach.
METHODS: Ki67-index was correlated with clinicopathologic parameters in 190 resected PanNETs. A validation cohort (n = 145) was separately analyzed.
RESULTS: In initial cohort, maximally selected rank statistics method revealed 12% to be the discriminatory cutoff (close to 10% rule of thumb). G2b cases had liver/distant metastasis rate of almost threefold higher than that of G2a and showed significantly higher frequency of all histopathologic signs of aggressiveness (tumor size, perineural/vascular invasion, infiltrative growth pattern, lymph node metastasis). In validation cohort, these figures were as striking. When all cases were analyzed together, compared with G1, the G2b category had nine times higher liver/distant metastasis rate (6.1 vs. 58.5%; p < 0.001) and three times higher lymph node metastasis rate (20.5 vs. 65.1%; p < 0.001).
CONCLUSIONS: G2b PanNETs act very similar to G3, supporting management protocols that regard them as potential therapy candidates. Concerning local management, metastatic behavior in G2b cases indicate they may not be as amenable for conservative approaches, such as watchful waiting or enucleation. This substaging should be considered into diagnostic guidelines, and clinical trials need to be devised to determine the more appropriate management protocols for G2b (10% to ≤ 20%) group, which shows liver/distant metastasis in more than half of the cases, which at minimum warrants closer follow-up.
Patients receive cetuximab, bortezomib (beginning at one dose level below the MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.
A personal body treatment product is disclosed for application to a user's body for hygienic, cosmetic, therapeutic, wellness purposes. The product includes a salt/mineral mass having salts and/or mineral ingredients capable of dissolving or dislodging from the mass in water at different rates. A sheath in the form of a bag encloses the mass, the sheath being composed of a porous material enabling water to penetrate the sheath so as to dissolve and/or dislodge ingredients of the mass and to enable ingredients to pass through the sheath to contact the user's body. The sheath encloses the mass so that the surface of the mass is not exposed in a manner to directly contact the user's body in use. The salt/mineral is composed of natural salts/minerals in a naturally adherent mass which is mined or harvested and subsequently shaped into a bar with rounded edges or corners, the bar being of a size to be comfortably grasped and held by hand. The sheath is made of a micromesh material so that substantially insoluble particulates in the mass and/or sparingly or relatively slowly soluble ingredients in the mass cannot pass through the micromesh material in particulate form to cause discomfort if rubbed along the user's skin. There is also provided a method of personal body treatment by providing and using the product.
PROBLEM TO BE SOLVED: To provide an electronic medicine delivery pen which can change the values of different modes such as time and date modes by an actuator when the actuator is removed from the drive mechanism of the pen. SOLUTION: This medicine delivery pen is equipped with a housing which has the proximal end and the distal end on the both sides. At the proximal end of the housing, the actuator, which sets and administers a dosage of medication, is disposed. The pen is equipped with a cartridge assembly containing the medication, having a cartridge equipped with a piston which is slidably and fluid-tightly engaged within the cartridge. The drive mechanism is coupled between the actuator and the cartridge, and a set dosage of the medication is injected by exerting a force in the axial direction to the piston. The actuator triggers the drive mechanism and injects the medication held in the cartridge. A processor is coupled to the actuator, and the actuator determines a value equal to the set dosage.
A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
Traditional neuropsychological models associate the medial temporal lobe (MTL) with episodic memory. Further, the hippocampus would be responsible for recollection, or the rich and contextualised retrieval of a memory; whereas the perirhinal cortex (PRC) would process familiarity, or the feeling that a stimulus has been encountered before, without remembering where or when it happened. However, there is growing evidence questioning this view, and supporting an alternative proposal. The representational view of the MTL proposes that such regions would not be organised according to cognitive processes, but rather according to the representations (or the mnemonic content, represented by a pattern of neuronal spikes. A 2018-fMRI study demonstrated that the engagement of the hippocampus in recollection depends on the presence of a spatial scene in the memory that is retrieved, and not on the reconstructive nature of the retrieval. However, this demonstration is incomplete, as the only process that was investigated is recollection. The current project aims to extend such results to memory processes such as familiarity, and even to non-mnemonic processes such as visual discrimination. A fMRI study will thus be conducted, where 30 healthy participants will first perform a visual-discrimination task on scenes and objects, before taking a recognition task, in which images will either be presented in full or in the form of circular cues only. Multivariate-Pattern Analyses (MVPA) will complete traditional fMRI analyses, in order to determine whether activity in the MTL can be categorised on the basis of representations through a machine-learning classifier.
The work will be done with 60 cashiers. These cashiers will be selected on the condition that they work at least 40 hours a week. 60 employees will be randomly divided into two groups of 30 people each. All participants will be given ergonomics training. In addition, participants in the exercise group will be given a 12-week exercise program. These two groups will be randomly divided into control and exercise groups. Each group will be evaluated twice, at the beginning and at the end of the study.
FIELD: medicine, experimental oncology. SUBSTANCE: invention proposes to use a physiological solution obtained by bubbling with ozone-oxygen mixture at the rate of gas flow 0.5-1 l/min for 15-20 min at ozone concentration in gaseous mixture 800-5 000 mcg/l. Solution is administrated into tumor directly by perimeter of its localization at volume 0.5-1.5 ml. Invention can be used for validity of the following study and using the ozonotherapy for treatment of patients with malignant neoplasms. EFFECT: broadened arsenal of treatment methods. 5 tbl, 3 ex
A gelatinous cosmetic base, e.g. for cleansing jellies, comprises water, at least one higher fatty acid or an ester thereof, higher unsaturated acid ester, higher aliphatic alcohol, wax or higher hydrocarbon and a surface-active agent which is a polyalkylene oxide ether of a higher monohydric aliphatic or araliphatic alcohol. Foaming agents and a detergent, e.g. the sodium or triethanolamine salt of polyoxyethylene lauryl sulphate may also be present.ALSO:A gelatinous cosmetic base comprises water, at least one higher fatty acid, higher aliphatic alcohol, higher fatty acid ester or unsaturated acid ester, wax or higher hydrocarbon and at least one surface-active agent which is a polyalkylene oxide ether of a higher monohydric aliphatic or araliphatic alcohol.  Additional ingredients include filmforming substances, vitamins, detergents, foaming agents, skin-nourishing agents, hormones, astringents, skin-softening agents, bleaching agents e.g. H2O2 and germicides.
BACKGROUND: Adjacent segment disease (ASD) is a common and serious complication that can develop in the mid- to long-term after lumbar fusion surgery. However, the underlying mechanisms of ASD are not yet fully understood. This study aimed to develop and validate a risk prediction model for ASD in patients who underwent transforaminal lumbar interbody fusion (TLIF) for lumbar degenerative diseases.
METHODS: Patients with lumbar degenerative disease who underwent TLIF between January 2015 and December 2016 were included in the retrospective study. The participants were divided into two groups: ASD and non-ASD. Univariate and multivariate logistic regression analyses were performed to identify factors influencing ASD after TLIF surgery. The receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) were used to evaluate the model's discrimination, calibration and clinical value, respectively.
RESULTS: A total of 11.5% (59/513) of patients developed ASD. Higher BMI, lower BMD, higher disc grade, and reduced disc height were identified as independent risk factors for ASD after TLIF. The model demonstrated good discrimination in both the training and validation sets, with calibration and Hosmer-Lemeshow tests confirming accuracy, and DCA demonstrating clinical applicability.
CONCLUSIONS: The nomogram model demonstrated promise in predicting ASD in patients who underwent TLIF, aiding clinicians in selecting the most suitable surgical approach and optimizing surgical decisions.
BACKGROUND: The tumour microenvironment (TME), which is modulated after immune-chemotherapy, is involved in tumour growth and metastasis. Programmed cell death 1 (PD-1) expressed on tumour-infiltrating non-malignant cells plays an important role in the TME through the PD-1/programmed cell death ligand 1 (PD-L1) signalling pathway. However, its impact in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains unclear.
METHODS: We conducted a retrospective study using tissue samples at relapse for patients with R/R DLBCL (n = 45) and evaluated the clinical impact of PD-1 expression on tumour-infiltrating non-malignant cells (microenvironmental PD-1, mPD-1). In addition, corresponding 27 samples at diagnosis were analysed to evaluate the changes in PD-1/PD-L1 expression in the TME after chemotherapy.
RESULTS: Patients with mPD-1+ DLBCL showed significantly better overall survival compared with patients with mPD-1- DLBCL (hazard ratio, 0.30, p = 0.03). Among patients with mPD-1- DLBCL, those positive for neoplastic or microenvironmental PD-L1 (nPD-L1+ or mPD-L1+ ) showed significantly worse outcomes. Microenvironmental PD-1 and PD-L1 expression has high correlation at relapse, although none was found at diagnosis.
CONCLUSION: We determined the clinical impact of microenvironmental PD-1 expression and its relationship with neoplastic or microenvironmental expression of PD-L1 in patients with R/R DLBCL. The expression of PD-1 and PD-L1 in the TME dramatically changes during the chemotherapy. Therefore, evaluating TME at relapse, not at diagnosis is useful to predict the outcomes of R/R DLBCL patients.
Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
PURPOSE: A dental filler containing composite glass fine flower and a crown material composition containing the same are provided to ensure excellent contrast and optical properties. CONSTITUTION: A dental filler contains composite glass fine powder containing Yb-combined material which is a contrast material. A crown material composition contains resin and filter. The refractive index difference of particles and resin is less than 0.1. The refractive index of the particles forming the composite glass fine powder is 1.45-1.55. The average particle size of the composite glass fine powder is 0.2-22 um. The composite glass fine powder contains Yb2O3 or YbF3 instead of barium or strontium and also contains Al_2O_3, SiO_2, and B_2O_3. The dental crown composition contains 5-50 wt% of Yb_2O_3 or YbF_3.
PURPOSE: A composition containing brown algae extract for activating GABA_A-benzodiazepine receptor is provided to ensure anti-anxiety and anti-convulsant effecta and to treat insomnia. CONSTITUTION: A composition for activating GABA_A benzodiazepine receptor contains brown algae extract as an active ingredient. The composition is used for anti-anxiety and anti-convulsant effect and treating insomnia. The brown algae include Ecklonia cava or Ecklonia kurome. The brown algae extract is water extract, ethanol extract, methanol extract, or mixture thereof. The water extract of brown algae is prepared by extracting brown algae using water of 40-100 Deg. C. for 2-48 hours. The ethanol extract is prepared by extracting brown algae with 35-75% ethanol at 20-60 Deg. C. for 2-36 hours.
Patients with moderate to severe allergic asthma who are poorly adherent to inhaled corticosteroids (ICS) have persistent airway inflammation that results in excessive morbidity and sometimes death. Omalizumab (OMB), an anti-IgE monoclonal antibody decreases the release of mediators from mast cells, reduces the frequency of exacerbations and allows a reduction in ICS dose. However, there are no data on the effects of OMB on airway inflammation. Bronchoprovocation with adenosine 5' monophosphate (AMP) is a robust and sensitive non-invasive measure of allergic airway inflammation, but the effect of OMB on this surrogate marker has not been previously reported. Based upon the mechanisms of actions of OMB and AMP and the fact that OMB will be administered at 2-4 week intervals in the clinic (i.e., direct observed therapy), it is our hypothesis that treatment with this new agent will reduce airway responsiveness to AMP and compensate for poor adherence to ICS.

To test this hypothesis, we will select 16 patients (6-26 yrs) with a total IgE of 30-1300 IU/ml, sensitivity to at least one allergen, an FEV1 ≥ 60% predicted, and documented poor adherence to ICS with inadequate asthma control. Subjects will be randomized to receive OMB (150-375 mg subcutaneously) or placebo every 2-4 weeks for four months each, in a double-blind, crossover manner with a 3 month washout period between treatments. Spirometry will be measured before each injection and at the end of each treatment period. The concentration of AMP that will provoke a 20% decrease in FEV1 (PC20 FEV1) and a free IgE serum concentration will be measured before and at the end of each treatment period. After randomization, a 5-day course of oral prednisone will be administered whenever bronchodilator-unresponsive symptoms persist or FEV1 is \< 60% predicted. ANOVA for repeated measures will be used to evaluate differences between treatments in Δ PC20 (primary endpoint) and Δ FEV1, while the Friedman Statistic will be used to evaluate differences in the number of short courses of prednisone. The results of this study will provide new information on the extent to which OMB decreases airway responsiveness to AMP (i.e. allergic airway inflammation) and whether this new therapy will fill an unmet need for patients who have inadequately controlled asthma because of poor adherence to inhaled corticosteroids.
A human laminin alpha2 chain LG1 domain and an active peptide are provided to promote cell adhesion used for a burn or wound medicine, an artificial nerve conduit or its scaffolds, and a scaffold for tissue engineering. A cell adhesion promoter includes polypeptides or its derivative composed of a LG1 domain sequence of a human laminin-2 alpha2 chain. The domain sequence is written as a sequence number 1. The cell adhesion promoter includes peptides or its derivative written as a sequence number 2. The cell indicates nerve cells. The polypeptide, peptide or derivatives thereof are coupled with syndecan-1 to adjust a position of protein kinase of C-alpha and PKC-delta within the cell.
Prodn. of sennosides A and B (I) comprises oxidising rheinanthrone-8-glucoside (II) with oxygen or an oxygen source in the presence of active charcoal as the catalyst. The (I) obtd. are converted into their Ca salts by treatment with an aq. soln. contg. Ca ions. (I) are laxatives which occur naturally, e.g. in senna plants.  Active charcoal is a more efficient catalyst than palladium black or a ferric salt previously used in the oxidn. of (II) and gives (I) in better purity and in yields which are > 30% higher. The Ca salts of (I) are more readily absorbed from the gastrointestinal tract.
FIELD: biotechnology, microbiology, agriculture. SUBSTANCE: invention relates to preparing strains of bacterium Pseudomonas fluorescens NCIMB 40490, NCIMB 40495, NCIMB 40497, Serratia liquefaciens NCIMB 40492, Serratia plymuthica NCIMB 40493. Also, invention relates to preparing strains of bacterium Bacillus pumilis NCIMB 40489 and Bacillus subtilis NCIMB 40491 used for the above indicated aim and for production of an antibiotic inhibiting a pathogen of the above indicated sicknesses. On the basis of the above indicated strains an aqueous suspension of microorganism is obtained that contains strains at concentration 10 4 -10 9  CFU/ml, preferably at concentration 10 5 -10 8  CFU/ml. Method of prophylaxis a fungal sickness in vegetables and/or fruits after harvest involves immersion of vegetables and/or fruits in an aqueous suspension containing one of the indicated strain of bacterium. On the basis of strains of bacterium Bacillus 40489 and 40491 an antibiotic (value Rf is about 0.39, or 0.56, or 0.61) is obtained that shows activity against Botrytis cinerea and Alternaria at pH 3.0-9.0. Antibiotic is obtained by culturing a strain of bacterium on medium containing cabbage leaves and water at ratio 5-100 g/1 l water. Antibiotic is isolated from filtrate of cultural fluid using columns with silica gel or plates and eluent consisting of butane-1-ol : acetic acid : water at ratio 3:1:1. Antibiotic and proposed strains ensure to safe fruit and vegetable harvest during storage by decay prevention. EFFECT: strains indicated above, enhanced effectiveness of an antibiotic. 16 cl, 12 tbl, 11 ex, 18 dwg